Belbuca Under FDA Review for Pain Management

Endo Pharmaceuticals and BioDelivery Sciences announced that the FDA has accepted for review its New Drug Application (NDA) for Belbuca (buprenorphine HCl) buccal film for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Two pivotal Phase 3 studies were conducted to demonstrate the safety and efficacy of Belbuca. The studies were double-blind, randomized, placebo-controlled, enriched-enrollment studies in patients with chronic lower back pain. One study (BUP-307) was conducted in opioid-experienced patients, and the second study (BUP-308) was conducted in patients naïve to opioid therapy.

Check out what's trending

More in Chronic Pain

A web-based cognitive behavior therapy program may be associated with greater reductions in aberrant drug-related behavior, pain interference, and pain catastrophizing in patients with chronic pain treated with opioids who ...